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Animal models of Alzheimer’s disease: modeling 
targets, not disease
Animal models of Alzheimer’s disease (AD) pathogenesis 
range from Caenorhabditis elegans to aged non-human 
primates, but by far the most widely used are rodent 
models. Most animal models used for drug discovery over-
express proteins with familial AD mutations (Table 1). 
While these models develop certain characteristics of 
AD-like pathology, they do not recapitulate the entirety 
of the human disease. Furthermore, it is unclear to what 
extent the pathogenic pathways in rodents mirror those 
in human AD. Other challenges in translation include 
mouse/human species diﬀ   erences (for example, diﬀ  er-
ences in cerebrovascular anatomy, neuronal network 
com  plexity, connectivity and disease susceptibility, white/
Abstract
Animal models have contributed signifi  cantly to our understanding of the underlying biological mechanisms 
of Alzheimer’s disease (AD). As a result, over 300 interventions have been investigated and reported to mitigate 
pathological phenotypes or improve behavior in AD animal models or both. To date, however, very few of these 
fi  ndings have resulted in target validation in humans or successful translation to disease-modifying therapies. 
Challenges in translating preclinical studies to clinical trials include the inability of animal models to recapitulate the 
human disease, variations in breeding and colony maintenance, lack of standards in design, conduct and analysis 
of animal trials, and publication bias due to under-reporting of negative results in the scientifi  c literature. The 
quality of animal model research on novel therapeutics can be improved by bringing the rigor of human clinical 
trials to animal studies. Research communities in several disease areas have developed recommendations for the 
conduct and reporting of preclinical studies in order to increase their validity, reproducibility, and predictive value. 
To address these issues in the AD community, the Alzheimer’s Drug Discovery Foundation partnered with Charles 
River Discovery Services (Morrisville, NC, USA) and Cerebricon Ltd. (Kuopio, Finland) to convene an expert advisory 
panel of academic, industry, and government scientists to make recommendations on best practices for animal 
studies testing investigational AD therapies. The panel produced recommendations regarding the measurement, 
analysis, and reporting of relevant AD targets, the choice of animal model, quality control measures for breeding 
and colony maintenance, and preclinical animal study design. Major considerations to incorporate into preclinical 
study design include a priori hypotheses, pharmacokinetics-pharmacodynamics studies prior to proof-of-concept 
testing, biomarker measurements, sample size determination, and power analysis. The panel also recommended 
distinguishing between pilot ‘exploratory’ animal studies and more extensive ‘therapeutic’ studies to guide 
interpretation. Finally, the panel proposed infrastructure and resource development, such as the establishment of a 
public data repository in which both positive animal studies and negative ones could be reported. By promoting best 
practices, these recommendations can improve the methodological quality and predictive value of AD animal studies 
and make the translation to human clinical trials more effi   cient and reliable.
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Page 3 of 13gray matter ratios, cellular redox conditions, and dynamics 
of drug/target interactions [1]). Nonetheless, rodent 
models oﬀ   er a means for testing pharmacodynamic 
proper  ties of candidate molecules on drug targets that 
may be involved in AD pathogenesis.
Th  is target-driven approach in animal models has 
already translated to therapeutic studies in humans. In 
the amyloid-beta (Aβ) immunotherapy trial of bapineu-
zu  mab, for example, the immunotherapy cleared plaques 
in both mice and humans [2,3]. Gamma-secretase inhibi-
tors developed at Eli Lilly and Company (Indianapolis, 
IN, USA) and Bristol-Myers Squibb Company (Princeton, 
NJ, USA) (semagacestat and BMS-708163, respectively) 
showed good target-focused preclinical animal data, 
reducing Aβ levels in mice and in the spinal ﬂ  uid  of 
human patients in a phase 2 study [4,5]. Demonstration 
of positive eﬀ  ects on cognitive outcomes from treatment 
with bapineuzumab of patients with AD is in the ﬁ  nal 
stages of clinical testing. Th  e phase 3 clinical trial of 
semagacestat was terminated prematurely because of 
lack of eﬃ   cacy as well as serious side eﬀ  ects [6], whereas 
clinical testing of BMS-708163 is in progress. Th  us,  while 
these examples provide reassurance that well-executed 
preclinical studies can translate to human patients with 
regard to pathological targets, they also highlight our 
limited understanding between causative pathways and 
clinical decline of cognitive function in AD and our 
inability to accurately model all aspects of the disease in 
animals.
Th  erefore, animal models appear more useful as 
models of speciﬁ  c disease targets and pathways than of 
the complete human disease. To optimize their use in 
that manner, our advisory panel recommended choosing 
models for preclinical studies that exhibit signiﬁ  cant and 
well-characterized pathology relevant to the disease 
process of interest (that is, amyloid plaques, tau 
pathology, neuronal loss, oxidative stress/inﬂ  ammatory 
changes, and so on). In addition, models that do not rely 
solely on mutated human genes to induce pathology are 
currently underused and can be quite informative. Th  ese 
include aged rodents, pharmacologically and surgically 
induced models, and other non-transgenic models 
(Table 1). Since there is no one model for AD, hypothesis 
testing in multiple models is preferable in order to 
provide better preclinical validation. In the following 
sections, we present the panel’s recommendations and 
guidelines for the design, execution, and interpretation of 
preclinical studies. Th  e objective of this panel was to 
improve the predictive value of animal models for clinical 
beneﬁ  t.
Know your model
Many transgenic lines show high variability in the extent 
and time course of expression of disease phenotypes. 
Table 2 illustrates common factors aﬀ  ecting phenotype 
variability, including environmental factors, age, sex, 
genetic background, litter, transgene copy number, and 
health status. Not all of these variables can be avoided, 
but measures can be taken so that phenotype changes 
due to such factors can be properly noted and potentially 
corrected [7-9].
Important points to keep in mind
• Maintain good communication among laboratory 
members to track deviations from expected pheno-
types. Keep careful records to track whether a change 
in phenotype occurs.
• Identify issues with breeding, such as longer litter 
intervals, smaller litter sizes, and fewer preg  nancies. 
Identifying such problems early will help keep 
production on track.
•  Screen gene copy numbers and transgene expression 
level regularly. Document and report.
• Freeze embryos early during characterization of the 
trans  genic line in case phenotypic drift necessitates re-
derivation of colony.
• Consider your genetic background: Mice may be 
healthier and more viable on a hybrid background, but 
genetic drift must be controlled to avoid confounding 
variables. Keep in mind that certain inbred strains are 
more prone to characteristics like blindness, hearing 
loss, and aggression.
•  If working with an outside breeder or contract research 
organization, ask to see historical data on the colony. 
Th  ese data should include rearing conditions such as 
light cycle, housing type, diet, and health status as well 
as breeding schemes to assess genetic management of 
the strain background(s) in the colony.
Improving rigor in study design
Many animal studies are ﬂ  awed by methodological weak-
nesses that compromise study validity and reproduci-
bility. In fact, it was reported that the majority of 
published eﬀ  ects in amyotrophic lateral sclerosis mice, 
for example, were likely measurements of noise in the 
sample population as opposed to actual drug eﬀ  ects [10]. 
By paying careful attention to study design before starting 
experiments, investigators can save time and money as 
well as minimize the probability of false-positive or false-
negative results. Table 3 outlines key study design con-
sidera  tions. In addition, performance on behavioral assays 
can be highly sensitive to protocol design. For the Morris 
water maze, for example, variables that can aﬀ  ect perfor-
mance include water tank size, number and kinds of 
visual cues, training protocol, how long animals are 
acclimated to the test room before testing, and strain 
diﬀ  erences (that can be diﬀ  erentially aﬀ  ected by genetic 
alterations or the aging process or both). It is important 
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mental design and use multiple overlapping tests to 
substantiate behavioral changes.
Develop and employ translatable biomarkers for animal 
preclinical studies
Biomarkers have been instrumental in revolutionizing 
the way we think about human AD and have allowed us 
to improve clinical trial design and assess target engage-
ment and response to treatments. Animal preclinical 
studies can also beneﬁ  t immensely from the use of bio-
markers to assess target engagement of investigative 
treatments, monitor biological responses to treatment in 
real-time, characterize the translatability of AD models, 
and determine the translatability of a novel therapeutic if 
the same biomarker can be used in a human clinical trial. 
Although more validation is needed, biomarker methods 
under development in rodents include imaging – mag-
netic resonance imaging (MRI), magnetic resonance 
spectroscopy, functional MRI, arterial spin labeling MRI, 
ﬂ  ouro-2-deoxy-D-glucose-positron emission tomography 
(FDG-PET), PET amyloid imaging, PET tau imaging, 
single-photon emission computed tomography/computed 
tomography, and others – and biochemical assays on 
biological ﬂ  uids such as plasma and cerebrospinal ﬂ  uid 
[11-13]. It is important to be aware of the limitations of 
these biomarkers in rodents, however. For example, func-
tional imaging in mice can be aﬀ  ected by the requirement 
for either anesthesia or restraint stress. Drawing cerebral 
spinal ﬂ  uid from mice is diﬃ   cult but doable, although it 
is important to avoid blood contamination [14]. Rat 
models are becoming more popular and may have 
advan  tages in these types of biomarker studies. In any 
case, whenever possible, biomarker measurements 
should be incorporated into the study design.
Timing of treatment
Treatment timing should depend on whether the thera-
peutic goal is disease prevention, therapeutic interven-
tion (that is, slowing/reversal of established pathology), 
or symptomatic relief. Tissue should be collected from a 
proper cohort of animals at the time when treatment is 
initiated to determine whether the treatment reduced 
pre-existing pathology in the brain or simply slowed its 
age-associated accumulation. Th   e degree to which 
disease stages in mouse models correlate with those in 
humans is currently unclear. Amyloid mice which do not 
show tangles or neuronal loss may be representative of 
presymptomatic or early-stage AD, although this idea is 
not universally accepted [15]. Where a longitudinal 
assessment is possi  ble (that is, using peripheral 
biomarkers, imaging, and certain behavioral responses), 
taking repeated measures of the same animal can be 
especially informative and add statistical power. 
Treatment should be timed on the basis of the optimal 
stage of pathology development in the animal, which will 
allow acceptable signal-to-background ratio and dynamic 
range for experimental treatments. Optimally, demon-
stra  tion of assay validation should be a prerequisite to 
embarking on therapeutic studies. Because pathology can 
vary widely with animal age, control and treatment 
groups should be age-matched to the greatest extent 
possible (that is, within days of one another). Pathology 
and biochemical readouts can also vary widely among 
animals within a genetically engineered line. Th  e varia-
bility in pathology with age and in outcome measures 
must be assessed in order to power the animal studies 
properly.
Pharmacokinetics/Pharmacodynamics, ADME-Toxicology
Studies should include pharmacokinetics (PK) and phar-
ma  co  dynamics (PD) assessments to determine whether 
the compound exposure is suﬃ   cient and whether it is 
interacting with the target of interest. Depending on 
whether a study is exploratory or therapeutic (see 
‘Exploratory versus therapeutic studies’), the degree to 
which absorption, distribution, metabolism, excretion, 
and toxicity (ADMET) are proﬁ  led should be considered 
as part of the prospective study design. In therapeutic 
studies, it is critical (a) to demonstrate that the test com-
pound has the capacity to reach its target with suﬃ   cient 
concentration and stability to be relevant to prior in vitro 
studies and (b) to guide the dosing concentrations and 
frequency to optimize the chance of achieving thera-
peutic eﬀ   ects. More information about these types of 
studies can be found in the Alzheimer’s Drug Discovery 
Table 2. Major factors aff  ecting phenotypic variability in 
mice
Environmental
  Housing system (type of caging/enrichment)
  Housing density (number of mice per cage)
 Handler/Investigator
 Light  cycle 
  Temperature and humidity 
  Noise and vibration
 Diet
 Health  status
Biological
 Age
 Sex
 Body  condition
 Genetic  drift
  Genetic background (mixed versus inbred)
  Type of background strain 
  Transgene copy number
  Transgene expression level
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Research Forum Drug Development Tutorial [16]. It is 
important to note that genetically engineered models 
may not always be the most cost-eﬀ  ective and translatable 
models for measuring PK/PD. Wild-type mice are often 
preferable for use in these studies, but correspondence 
with genetic background strains in the transgenic studies 
should be considered.
Statistical analysis plan and methods
Statistical methods should be chosen before a study is 
begun, with the anticipated direction of change (one-
sided or two-sided) in mind. Statistical considerations 
should be clearly stated in the Methods section of all data 
reporting. Assessment of endpoint variability in a large 
sample size is necessary and should be considered in the 
choice of statistical tests, as the type of variability (normal 
distribution versus skewed) dictates a parametric versus 
non-parametric statistical analysis of the data. Guidance 
or consultation of a statistician should be enlisted in the 
design of the study once the endpoint variability has been 
characterized.
Proper quantifi  cation
Both the area and magnitude of pathology should be 
quantiﬁ   ed and reported. Adequate tissue sampling is 
critical for accurate estimation of pathological burden. 
For imaging, typically at least six or seven ﬁ  elds  per 
section and six or seven sections per mouse (sampled 
across multiple aﬀ   ected brain regions) should be 
measured. Th   e use of unbiased stereology and the optical 
fractionator method is critical to determining an accurate 
and statistically reliable neuronal count in brain sections 
[17]. Staining and ﬁ  eld sampling methods should always 
be stated in the Methods section, and sampling should be 
guided by statistical considerations of the variability in 
the endpoint being interrogated. Analysis and quantiﬁ  -
cation of pathology should be conducted by an individual 
who is blind to the treatment condition.
Sample size
Animal studies are frequently underpowered. Th  is was 
reported to be the single most important factor in inﬂ  u-
encing spurious research results with animal models [10]. 
Minimum sample size depends on the expected magni-
tude of the biological eﬀ  ect, the inherent variability of the 
target being measured (for example, cerebral spinal ﬂ  uid 
Aβ is much more variable than hippocampal Aβ), 
variability in behavioral measures or other outcomes, and 
other factors such as variations in survival within the 
particular cohort of animals. It is critical to be aware of 
the natural variability within and among animals in 
outcome measures in non-treated animals in order to 
determine the number of animals required for proper 
statistical powering of therapeutic eﬀ  ects.  Th  e sample 
size needed to achieve signiﬁ  cant diﬀ  erences given the 
variability of disease outcomes in most AD mouse 
models has been estimated to be on the order of 20 to 30 
per group, rarely achieved in most published mouse 
studies.
Exclusion criteria
Animals whose physiological condition appears to be 
compromised by factors unrelated to the normal 
progression of the disease should be excluded from the 
study. A statistical analysis plan should be developed to 
Table 3. Key considerations for preclinical animal studies
Clearly delineate an a priori hypothesis for the study and include primary and secondary outcomes
  Prespecify a specifi  c measure to assess the primary and secondary outcomes.
  Attempt to employ translatable biomarkers.
  Consider issues of sex, timing of treatment, and age of animals. 
  Determine inclusion and exclusion criteria.
  Demonstrate that the therapeutic compound reaches its intended target in a suffi   cient concentration to ensure that the hypothesis is being tested.
Carefully design a statistical analysis plan prior to initiation of the study
  Perform power analysis and sample size estimates prior to initiation of the study and take into account previously measured variability in the outcome 
 measures.
  Include randomization methods for treatment groups and blinding procedures for those doing assessments.
  Include procedures for dealing with dropouts and deaths of animals in statistical analyses.
Reduce publication bias
  Report both positive results and negative ones in peer-reviewed journals or other open-access format.
  Report details of strain, housing, diet, dropout events and in-trial exclusions so that variables can be assessed.
  As in clinical trials, report the fl  ow of animals through the treatment plan of the study.
  Indicate potential confl  icts of interest and whether investigators are third-party or primary  investigators invested in the hypothesis.
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established prior to the study and not on a post hoc basis. 
Records should be kept of which animals were excluded 
and why, and such information should be reported 
explicitly in the Methods section of data reporting.
Balancing and randomization
Sex-matching and age-matching are critical in study 
design as both of these factors signiﬁ  cantly aﬀ  ect patho-
logical expression. For example, Aβ plaque loads can 
increase exponentially during the ﬁ  rst stages of plaque 
deposition, and spurious drug eﬀ   ects may be seen in 
animals analyzed at this stage unless control and 
treatment groups are age-matched to within days of one 
another. Mice should be separated into groups by sex, 
age, and litter and then randomly assigned to either 
control or treatment groups. In addition, wild-type or 
young controls or both should be included in study 
design as a reference point.
Blinding
Individuals conducting the experiments and those 
analyz  ing the results should be blinded to treatment. In 
the event that a test compound has a readily obvious 
phenotypic impact on the treated animals, these poten-
tially unblinded observations should be noted by the 
animal handler but kept segregated to the degree possible 
from the analyst until the experiment is un  blinded. If this 
is not possible, a full re-design of the experiment may be 
required. For example, a compound that results in 
reduced feeding activity (and the pheno  typic observation 
of reduced rate of weight gain) may have an impact on Aβ 
levels for reasons unrelated to its therapeutic target.
Reporting
Investigators should report full details of target assay 
methods and detailed information on the animal model 
used, including genetic background, copy number, exclu-
sion criteria, and statistical analyses. For behavioral 
assays, training as well as testing phases should be 
reported. When possible, scatter-plots should be shown 
rather than, or in addition to, bar graphs.
Publication bias fueled by a decreased ability or desire 
to publish negative results represents a huge problem for 
the ﬁ  eld [18]. To increase eﬃ   ciency, decrease redundant 
eﬀ  orts, and learn from others’ experiences, it is crucial 
that negative results be reported. Forums for discussing 
the quality of negative results, and results that diﬀ  er from 
laboratory to laboratory, would aid in the interpretation 
of negative studies.
Exploratory versus therapeutic studies
Many investigators, particularly in academic settings, 
lack the infrastructure and budget to perform the 
extensive preclinical studies incorporating all of the 
design, methodological, and statistical considerations 
recom  mended here. In addition, comprehensive analyses 
are not always warranted when the compound or target is 
being assessed in early stages. As a result, we propose to 
distinguish between exploratory and therapeutic studies 
(Table 4).
Exploratory studies
Exploratory studies should demonstrate that a particular 
molecular target is involved in a disease process. While 
exploratory studies do not require the extensive lead 
optimization, PK/PD, and toxicity analyses undertaken in 
therapeutic studies, they nonetheless should provide 
suﬃ     cient data to inform the decision of whether to pro-
ceed to a therapeutic animal study. Exploratory studies 
should contain a tolerability/toxicity assay to verify that 
selected doses are not causing an adverse eﬀ  ect. Multiple 
doses below the toxicity/tolerability range should be 
incorporated into an exploratory study, as doses 
approaching tolerability limits can frequently impact 
phenotypic outcomes unrelated to the therapeutic target 
being investigated. Furthermore, terminal blood and 
brain tissue samples should be collected for possible PK 
veriﬁ  cation later, as the half-life of the test compound 
may or may not have been consistent with the timing of 
the putative therapeutic readout.
Therapeutic studies
Th  erapeutic  studies should be compound-focused and 
include a full PK/PD and ADMET proﬁ   le to ensure 
appro  priate dosing and timing of outcomes with respect 
to exposure of the compound. Toxicity considerations are 
particularly critical in this context to minimize potential 
oﬀ  -target phenotypic impacts on outcome measures. Th  e 
design, conduct, analysis, and reporting of a therapeutic 
animal study should be analogous in rigor to those 
required for human clinical trials.
Future directions
Below, we list some overall recommendations and chal-
len  ges that we hope will signiﬁ  cantly advance the ﬁ  eld by 
making animal studies more consistent and predictive of 
future clinical outcomes.
Improve access, characterization, and standardization of 
existing Alzheimer’s disease mouse and rat models
Th  e ﬁ   eld should identify a few models in which key 
disease phenotypes are well replicated and characterize 
these models fully with regard to major targets and how 
they are aﬀ  ected by major biological and experimental 
variables (for example, age, gender, and housing condi-
tions). Government funding of preclinical animal cores 
could improve availability and standardization of models. 
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model access. Th   is is a major impediment that needs to 
be addressed by the scientiﬁ  c and business communities.
Develop more animal models to non-traditional targets 
and make more use of available non-transgenic models
New animal models that better recapitulate the full 
complement of human AD pathology and novel non-
amyloid targets are needed (Box  1). Aged rodent and 
non-transgenic models should also be better used as 
described above.
Standardize commonly used protocols
To be better able to compare and pool research results, it 
is important to improve quality control measures across 
laboratories. Eﬀ  orts to standardize biomarker protocols 
have been widely successful [19]. Standardizing protocols 
for common assays, such as Aβ/tau extraction, behavioral 
assays, and measures of neuroprotection and neuro-
degeneration, in preclinical studies could rapidly advance 
the interpretation of the testing of novel treatments.
Develop new and higher throughput methods for 
measuring disease-related outcomes
Research eﬀ  orts and funding should be targeted toward 
better characterizing and developing new methods for 
targets and outcome measures that are higher throughput 
for drug discovery. For example, for oxidative stress and 
inﬂ  ammation, more emphasis should be placed on the 
development of pharmacological and metabolic imaging, 
gene expression, and proteomic screens that provide a 
broader view of redox and inﬂ  ammatory changes and 
allow incorporation of both pro- and anti-oxidant or pro- 
and anti-inﬂ  ammatory species. For behavioral tests, the 
ﬁ  eld would beneﬁ  t from new translatable behavioral tests 
that are sensitive to early changes and progression in 
cognitive function across lifespan and those that lend 
themselves to repeated testing for optimal within-subject 
experimental design. Standardization of behavioral 
methodologies should be attempted to the highest 
possible degree in order to improve the ability for 
comparisons of results from multiple laboratories.
Focus on novel targets and outcome measures
More emphasis should be placed on non-amyloid disease 
processes and pathways (Box 1), including those related 
to neuroprotection, synaptic plasticity, oxidative stress, 
inﬂ  ammation, vascular targets, mitochondria, and energy 
use. Assays are available to measure these alternative 
outcomes.
Standardize review of animal studies in grant applications 
and scientifi  c publications
Our advisory panel recommended developing a study 
design checklist of items for consideration by funding 
agencies and scientiﬁ  c journals (Table 3). A rating system 
on study design quality of published papers and a 
centralized website that lists study results with a forum 
for comments and feedback would help to improve the 
selection of compounds for promotion into clinical trials. 
Furthermore, it would increase the incentive among 
academic researchers to improve study design.
Establish a public data repository for animal studies
A public data repository for both positive data and nega-
tive data from animal studies would help to improve 
research eﬃ   ciency and disseminate negative data. Given 
that it is often diﬃ     cult to distinguish a true negative 
result from a poorly designed study, the critical challenge 
of such a resource would be quality control. Th  e con-
siderations listed above will be important in providing 
this sort of distinction and will enable analyses of studies 
with various strengths and weaknesses in design. Such a 
repository could help to identify translatable biomarkers 
Table 4. Exploratory versus therapeutic preclinical studies
Goal  Exploratory studies: mechanism/target-focused  Therapeutic studies: compound-focused
Study design  Effi   cacy data should be assessed through multiple outcome   Effi   cacy results should be demonstrated in more than one model.
 measures. 
  Both exploratory and therapeutic studies should be randomized, placebo-controlled, and blinded, with a dose response.
  In vivo model considerations for both types of studies include pathogenic stage, age, length of treatment required, and exclusion criteria.
ADME  Studies should include initial physicochemical property   Studies should include ADME profi  ling, full pharmacokinetics/
  considerations and terminal blood and brain tissue sampling  pharmacodynamics analysis and distribution/exposure of parent
  for assurance of target exposure and possible pharmacokinetics  compound and metabolites.
 verifi   cation. 
Toxicity  Defi  ned toxicity assessment is not needed, but a simple drug  Toxicology should be assessed in the model being studied, with 
  tolerability assay should be included.  treatment conducted at levels reliably below adverse event doses.
Statistics plan  While statistical considerations need not be as stringent,   Prospective study design should include sample size power
  prospective power analysis should take into account variability   analyses, statistical evaluation plan, primary and secondary outcome
  in the model itself and in outcome measure readouts.  measures, blinding, and randomization.
ADME, absorption, distribution, metabolism, and excretion.
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Page 8 of 13Box 1. Thinking beyond amyloid: diversifying across disease processes
While many reasons, including clinical study design, may have contributed to the high-profi  le clinical trial failures with anti-amyloid 
treatments to date, the AD fi  eld would benefi  t from diversifying its research portfolio to include non-amyloid disease pathways. 
Understudied disease processes include neuronal function, vascular changes, oxidative stress and infl  ammation, mitochondria function, 
and lipid metabolism. Here, we list methods that can be used to assess some of these processes and that should be more fully exploited.
Neuronal function
As Alzheimer’s disease (AD) progresses, loss of synapses, shrinkage of dendrites, and neuronal death occur. It is these pathological changes 
that are most closely associated with the cognitive decline seen in the human disease. They can be modeled to some degree in a number 
of diff  erent animal models and are amenable to experimental monitoring as outlined below.
•  Measure synaptic density by immunohistochemistry for the synaptic markers, such as synaptophysin. Non-homogeneity of synaptic 
markers in tissue surrounding plaques can present challenges in analysis. Also, PSD-95, AMPA-R, immediate early genes, and others are 
better markers for synaptic function than synaptophysin.
•  Assess dendritic branching, neuronal structure volume, and total neuron numbers with careful stereology [22].
•  Use T2-weighted magnetic resonance imaging (MRI) to indirectly assess neurodegeneration in vivo by measuring structure volumes, and 
use 1H magnetic resonance spectroscopy (1H MRS) to quantify N-acetyl-aspartate levels [23].
•  Use electrophysiology to measure long-term potentiation in hippocampal slices.
•  Employ behavioral studies to assess neuronal function. The Morris water maze, a spatial memory test that can be very sensitive to 
hippocampal function, is most commonly employed, but alternatives are available that may detect more subtle changes or may 
be more readily translatable – including attentional set shifting, delayed non-match-to-sample, recognition memory (novel object 
recognition), discrimination and reversal learning, contextual fear conditioning, and olfaction-based assays – or both [24-26]. Multiple 
behavioral tests may be needed to fully capture potential therapeutic eff  ects. The use of multiple tests also helps control for factors, such 
as motivation and overall health, that may infl  uence performance.
Vascular targets
Vascular pathology in human AD has received little attention, despite increasing evidence that vascular and neuronal dysfunction are 
closely intertwined and mutually exacerbating in the human disease. For example, cerebral amyloid angiopathy is seen in over 75% of 
patients with AD and can lead to vessel rupture, microbleeds, and hemorrhagic stroke [27,28]. Other vascular changes include reduced 
cerebral blood fl  ow, degeneration of vascular endothelium, basement membrane and smooth muscle, and pathological changes in the 
neurovascular unit associated with astrocytes, pericytes, and microglia [29]. Attention to vascular targets is further warranted by evidence 
that amyloid-beta (Aβ) immunotherapy exacerbates cerebral amyloid angiopathy and microhemorrhages in both mouse AD models and 
human AD [30]. Experimental methods for monitoring vascular pathology include the following:
•  Detect microhemorrhages with Prussian blue and double-stain for vascular Aβ. T2-weighted MRI can also be used.
•  Assess blood vessel area and patency (quantify using stains, such as tomato lectin, that bind to endothelial cells, together with imaging 
analysis). Counterstain for components of healthy blood vessels (for example, smooth muscle actin).
•  Quantify retinal hemodynamics, which may be translatable as a biomarker in humans [31].
•  Measure blood fl  ow directly by arterial spin labeling and dynamic susceptibility contrast MRI and indirectly by FDG-PET or SPECT 
imaging. Blood volume can be sensitively measured by monocrystalline iron oxide nanoparticle-enhanced MRI.
•  Assess the structural integrity of the neurovascular unit by glial fi  brillary acetic protein staining and counting total numbers of astrocytic 
end-feet and the number in contact with blood vessels.
•  Assay neurovascular unit function by immunocytochemistry, quantitative polymerase chain reaction, or Western blot measurement 
of aquaporin 4 or potassium channels (Kir4.1, BK calcium-dependent potassium channel) that are enriched in astrocytic end-feet. It 
is important to do immunohistochemistry in addition to biochemical measurements as channel distribution can be altered without 
changes in total levels.
Oxidative stress/Infl  ammation
Oxidative stress and infl  ammation are known to be associated with AD and are relevant targets for drug development, in particular for 
sporadic AD. However, detecting reliable changes in AD models can be quite diffi   cult.
High oxidative stress is not seen in the most commonly used amyloid precursor protein transgenic (Tg2576) but can be seen in more 
recent models in which redox pathways have been genetically manipulated [32-34]. These models also show more aspects of AD 
pathology. Diff  erent animal models vary in their upregulation of specifi  c infl  ammatory profi  les; tau models, in particular, show high levels 
of infl  ammation in association with neurodegeneration. The time points in which these pathways are assessed is critical since oxidative 
and infl  ammatory processes that are toxic at one time point may be protective at others; their levels and eff  ects may also vary among 
brain regions.
Continued overleaf
Shineman et al. Alzheimer’s Research & Therapy 2011, 3:28 
http://alzres.com/content/3/5/28
Page 9 of 13in animal models that can also be used in human clinical 
trials to better predict outcomes.
Conclusions
Our advisory panel produced recommendations in 
regard to the measurement, analysis, and reporting of 
relevant targets in AD animal models. Th  ese  recommen-
dations stressed the need for quality control measures in 
breeding and colony maintenance to manage phenotypic 
variability and outlined key issues related to preclinical 
animal study design. Distinguishing between exploratory 
and therapeutic animal studies will aid in deﬁ  ning the 
scope of the study and the interpretation of results and 
hopefully will bring some of the rigor of industry 
preclinical testing to the academic space.
Whereas Aβ likely plays a key role in the development 
of AD, amyloid deposition alone does not represent the 
entirety of the disease process or the totality of targets 
worth investigating for therapeutic intervention. To 
propel innovation, we should broaden our focus to 
additional disease-relevant pathways and processes (such 
as tauopathy, neuroprotection, synaptic plasticity, oxida-
tive stress, inﬂ   ammation, vascular changes, and mi  to-
chon  drial dysfunction). Furthermore, non-transgenic 
models of disease are often underused. Aging is the 
greatest risk factor for AD; hence, aged rodent models 
that show cognitive impairment may provide a useful 
choice for testing investigational therapies targeting 
mechanisms of neuroprotection, learning, and memory. 
In addition, models that demonstrate clear neuro-
degenera  tion and cell death (such as tau transgenic 
models and pharmacologically induced models) may be 
better for testing neuroprotective therapies in general. 
Th  ere is no standard model or set protocol for testing 
investi  gational treatments in AD, and it is critical to tailor 
the choice of model, experimental plan, and outcome 
measures speciﬁ  cally for the therapy’s target or proposed 
mechanism of action. Animal models of disease will 
never be able to predict all possible outcomes in humans.
While these recommendations are speciﬁ  cally  geared 
toward AD, they echo many of the sentiments raised in 
other recent consensus eﬀ  orts for related diseases such as 
stroke, vascular cognitive impairment, and amyotrophic 
lateral sclerosis [10,20,21]. Th  ese  eﬀ  orts, as a whole, high-
light common challenges in animal model selection, study 
design, interpretation, and reporting which go beyond 
individual disease states. While each therapeutic area will 
undoubtedly have its own unique issues, there is much to 
be learned from shared barriers in translational research. 
Hopefully, these collective eﬀ  orts will raise the bar for 
preclinical studies and will aid in designing animal studies 
to optimize their interpreta  bility, improve their predictive 
value, and drive inno  vation, ultimately improving our 
eﬃ   ciency in bringing eﬀ  ective treatments to patients.
Box 1. Continued
Because reactive species are labile and cannot be measured directly, oxidative stress must be measured via surrogate markers:
•  Chronic oxidative stress can be detected by monitoring lipid peroxidation or oxidized proteins (by carbonyl assay or by high-
performance liquid chromatography) or by quantifying changes in genes and proteins known to increase or decrease with cellular 
redox balance [35].
•  Commonly used markers also include oxidized DNA and anti-oxidant proteins (such as glutathione, which is known to be directly 
aff  ected by Aβ).
•  Free iron, copper, and zinc can be measured. Free iron is a linear indicator of disease progression in many neurodegeneration models 
and is an indicator of free radical generation around Aβ.
•  Many of these assays have low sensitivity and so likely will detect only robust drug eff  ects. The more sensitive assays require mass 
spectrometry or high-performance liquid chromatography or 31P and/or 1H MRS.
•  Emerging technologies include two-photon imaging with novel probes for reactive oxygen species, which could be used to separately 
monitor changes occurring in the parenchyma and vasculature.
Infl  ammation can be assessed by the following:
•  Measuring invasion of peripheral cells or microglial activation or both. The number and morphology of microglia in tissue sections can 
be quantifi  ed.
•  In vivo imaging of microglial activation markers (for example, PK11195 positron emission tomography imaging, autoradiography, or 
tissue sample scintillation counting). Not all of these markers are well characterized in terms of when during the infl  ammatory process 
microglia express them.
•  Testing for blood-brain barrier leakage, which can be detected by steady-state gadolinium-enhanced T1-weighted MRI or classical 
intravenous bovine serum albumin and/or Evans blue brain parenchyma quantifi  cation. Related cerebral edema can be quantifi  ed by 
diff  usion or absolute T2-weighted MRI or both.
FDG-PET, fl  uro-2-deoxy-D positron emission tomography; SPECT, single-photon emission computed tomography.
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